## Supplement:

## SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients

Authors: Harold J. Manley<sup>1</sup>, Gideon N. Aweh<sup>1</sup>, Caroline M. Hsu<sup>2</sup>, Daniel E. Weiner<sup>2</sup>, Dana

Miskulin<sup>2</sup>, Antonia M. Harford<sup>1</sup>, Doug Johnson<sup>1</sup>, Eduardo K. Lacson<sup>1,2</sup>

- 1. Dialysis Clinic Inc., Nashville, TN
- 2. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

Table S1. COVID-19 infection and COVID-related hospitalization/death rates per 10,000 patient days and vaccine effectiveness between June 27 and October 2, 2021 in patients vaccinated during Delta dominant period.

	Last Vaccination Status*	Person Days at Risk	Events within 30 days COVID-19 diagnosis	Rate per 10,000 days	Adjusted Hazard Ratio (95% CI)	Vaccine Effectiveness (95% CI)
COVID-19 infection						
Unvaccinated	2660	274,527	217	7.9	Reference	Reference
Partially Vaccinated	467	41,541	24	5.8	0.73 (0.47,1.11)	27%
Fully Vaccinated	636	31,411	11	3.5	0.43 (0.24,0.79)	57%
BNT162b2/Pfizer	321	14,325	9	6.3	0.75(0.38,1.47)	25%
mRNA-1273/Moderna	268	14,315	1	0.7	0.09(0.01,0.62)	91%
Ad26.COV2.S/Janssen	47	2,771	1	3.6	0.48(0.07,3.47)	52%
COVID-related hospitaliza	ation/death					
Unvaccinated	2660	282,368	86	3.05	Reference	Reference
Partially Vaccinated	467	42,216	10	2.37	0.69(0.36,1.34)	31%
Fully Vaccinated	636	31,696	4	1.26	0.37(0.14,1.02)	63%
BNT162b2/Pfizer	321	14,595	4	2.74	0.79(0.29,2.16)	21%
mRNA-1273/Moderna	268	14,325	0	0.00	n/a	n/a
Ad26.COV2.S/Janssen	47	2,776	0	0.00	n/a	n/a

CI = confidence interval; n/a = not applicable; \* = Although patients can contribute time to any vaccination status, the N in the first column refers to patients' status at the end of follow-up. Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were  $\geq 14$  days after the first mRNA vaccine dose but < 14 days after the 2n d mRNA vaccine dose; fully vaccinated patients includes all patients  $\geq 14$  days after the last vaccine dose.

Adjusted for age, days since full vaccination status, female, number of comorbidities, race (white = reference), congregate living (e.g., nursing home, long-term care facility), hemodialysis single pool  $Kt/V \ge 1.2$  or peritoneal dialysis weekly  $Kt/V \ge 1.7$ , albumin, Hepatitis B seroimmunity defined as hepatitis B surface antibody  $\ge 10 \, \text{mIU/mL}$ , disability, diabetes, hypertension, peripheral vascular disease, thyroid disease, cancer, county rates for Biden voters and daily rate of COVID infection.

Table S2. Parameter hazard ratios against COVID-19 related hospitalization or death.

Parameter	pre-Delta variant period	Delta variant dominant period	
	Hazard Ratio	Hazard Ratio	
	(95% Confidence Interval)	(95% Confidence Interval)	
Unvaccinated	Reference	Reference	
Partially Vaccinated	1.21 (0.77, 1.90)	0.79 (0.44, 1.42)	
Fully vaccinated BNT162b2/Pfizer	0.22 (0.07, 0.67)	0.17 (0.10, 0.31)	
Fully vaccinated mRNA-1273/Moderna	0.08 (0.02, 0.30)	0.09 (0.05, 0.17)	
Fully vaccinated Ad26.COV2.S/Janssen	0.55 (0.12, 2.61)	0.19 (0.08, 0.43)	
Weeks since full vaccination status	1.04 (0.93, 1.17)	1.17 (1.11, 1.23)	
Age (per decade)	1.29 (0.82, 2.05)	0.94 (0.86, 1.04)	
Female	1.55 (1.10, 2.20)	1.08 (0.83, 1.40)	
Race - Black (reference = White)	1.03 (0.69, 1.54)	1.10 (0.82, 1.47)	
Race - Other (reference = White)	1.22 (0.75, 1.99)	1.02 (0.70, 1.48)	
Congregate living <sup>a</sup>	2.12 (1.37, 3.28)	1.97 (1.44, 2.70)	
Albumin g/dL (continuous)	1.00 (0.69, 1.45)	0.47 (0.37, 0.60)	
Hepatitis B surface antibody ≥ 10 mIU/mL	0.70 (0.47, 1.03)	0.67 (0.47, 0.95)	
History of failed transplant	0.49 (0.18, 1.33)	0.44 (0.19, 0.99)	
Number of comorbidities	0.92 (0.81, 1.04)	1.08 (1.00, 1.18)	
Diabetes	0.97 (0.66, 1.42)	1.39 (1.03, 1.88)	
Hypertension	1.52 (0.88, 2.62)	1.16 (0.76, 1.77)	

 $<sup>^</sup>a$  = Residing in nursing home or long-term care facility; Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were  $\geq$ 14 days after the first mRNA vaccine dose but <14 days after the 2nd mRNA vaccine dose; fully vaccinated patients includes all patients  $\geq$ 14 days after the last vaccine dose.

Table S3. Parameter hazard ratios against COVID-19 related hospitalization or death in patients vaccinated during Delta variant dominant period.

Parameter	Hazard Ratio		
	(95% Confidence Interval)		
Unvaccinated	Reference		
Partially Vaccinated	0.85 (0.44, 1.61)		
Fully vaccinated BNT162b2/Pfizer	0.56 (0.10, 3.26)		
Fully vaccinated mRNA-1273/Moderna	n/a		
Fully vaccinated Ad26.COV2.S/Janssen	n/a		
Weeks since full vaccination status	1.05 (0.79, 1.40)		
Age (per decade)	0.91 (0.80, 1.03)		
Female	1.40 (0.96, 2.04)		
Race - Black (reference = White)	1.16 (0.77, 1.74)		
Race - Other (reference = White)	1.22 (0.71, 2.10)		
Congregate living <sup>a</sup>	2.01 (1.27, 3.22)		
Albumin g/dL (continuous)	0.75 (0.52, 1.07)		
Hepatitis B surface antibody ≥ 10 mIU/mL	0.58 (0.16, 2.07)		
History of failed transplant	0.50 (0.16, 1.60)		
Number of comorbidities	1.13 (1.00, 1.28)		
Diabetes	1.23 (0.81, 1.88)		
Hypertension	1.39 (0.74, 2.64)		

a = Residing in nursing home or long-term care facility; Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were ≥14 days after the first mRNA vaccine dose but <14 days after the 2nd mRNA vaccine dose; fully vaccinated patients includes all patients ≥14 days after the last vaccine dose

Figure S1. Cumulative percent COVID-19 breakthrough infections relative to days since full vaccination status overall (panel A) and by vaccine type (panel B)

